Jessica Merrill

@Jessicaemerrill

pharma reporter, writer, reader, vermonter, patriot, mom.

Brooklyn, NY
Vrijeme pridruživanja: ožujak 2014.

Tweetovi

Blokirali ste korisnika/cu @Jessicaemerrill

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Jessicaemerrill

  1. 's effort to get smaller follows a growing industry trend among big pharmas to focus on select therapeutic areas and high-growth innovative brands. But Merck's decision came as a bit of a surprise; CEO Frazier said it was considered for some time.

    Poništi
  2. spent 10 years thinking about a split.... not so much.

    Poništi
  3. proslijedio/la je Tweet
    prije 17 sati

    splitting into two: 1. biopharma company focused on 'science related to the immune system, use of genetics and new technologies'. 2. leader in consumer healthcare.

    Poništi
  4. proslijedio/la je Tweet

    Merck will spin off about 90 products forecast sell $6.5 billion this year, including cholesterol drug Zetia, into a new, publicly-traded company next year.

    Poništi
  5. 31. sij
    Poništi
  6. 30. sij

    Breakfast for dinner is when you are failing as a parent...or winning?

    Poništi
  7. 30. sij

    will increase spending in 2020 to build out a commercial infrastructure to support the launch of and its already starting

    Poništi
  8. 30. sij

    don't count 's out; $660m in 2019 sales, despite a big price cut. 's Xeljanz was a many years ramp to blockbuster status too.

    Poništi
  9. 30. sij

    revenues of $568m, of $738m and of $911m in 2019; looks like biosimilars are becoming material to the top line. But for each company it is a portfolio of products and US and Europe.

    Poništi
  10. 29. sij

    made $390m in 2019, approved midyear in children under 2. It's on a partial trial hold in older patients. I talked to President Lennon on the relationship with FDA, the clinical hold and expansion in gene therapy

    Poništi
  11. 29. sij

    ' Sandoz is discontinuing development of a generic after around 10 years of investment and a CRL from FDA in 2018. 's Wixela remains the only one so far to get to market in the Us, despite attempts by a lot of players.

    Poništi
  12. 28. sij

    Pretty interesting that after such a slow start 's business has grown into a nearly billion dollar business, up 22% to $911m in 2019.

    Poništi
  13. 28. sij

    confirms it has submitted the first NGF inhibitor tanezumab to FDA for pain in osteoarthritis at the lower 2.5mg dose. Tanezumab is partnered with

    Poništi
  14. proslijedio/la je Tweet
    27. sij
    Poništi
  15. 27. sij

    I talked to new pharma president about several launches and how the company is viewing as a "vaccines-like" approach to cholesterol.

    Poništi
  16. 23. sij

    Payers are easing restrictions, like step edits, among branded I&I drugs, according to a Bernstein analysis. is not a required step edit in dermatology or RA anymore, and that could have implications for biosimilars eventually.

    Poništi
  17. 22. sij

    The extra week between New Year's and was great. But the downer is that S&E start today with

    Poništi
  18. 21. sij

    FDA believes this is the first study to investigate a variety of proprietary prescription drug names. story by

    Poništi
  19. proslijedio/la je Tweet
    16. sij

    What a week it’s been - and it’s only Thursday! Here’s our (free) Day 3 roundup. One more Notebook to come & many stories to follow over the coming weeks from insightful interviews & did on the ground in San Francisco.

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·